Transient receptor potential canonical 5 (TRPC5) protects against pain and vascular inflammation in arthritis and joint inflammation.
Khadija M AlawiFiona A RussellAisah A AubdoolSalil SrivastavaYanira Riffo-VasquezLineu BaldisseraPratish ThakoreNurjahan SalequeElizabeth S FernandesDavid A WalshSusan D BrainPublished in: Annals of the rheumatic diseases (2016)
Genetic deletion or pharmacological blockade of TRPC5 results in an enhancement in joint inflammation and hyperalgesia. Our results suggest that activation of TRPC5 may be associated with an endogenous anti-inflammatory/analgesic pathway in inflammatory joint conditions.